U.S.-Israeli Firm Develops Drug for Critically Ill Covid Patients

U.S.-Israeli NeuroRx pharmaceutical company, partnered with Geneva-based Relief Therapeutics Holdings, has developed RLF-100, or aviptadil, a synthetic form of a natural peptide that protects the lung, for treating critically ill Covid-19 patients, Reuters reports.

Patients recovered rapidly from respiratory failure after three days of treatment with RLF-100, a therapy granted fast-track designation in the U.S., the two drug companies said on Sunday.

Similar results were seen in more than 15 patients treated under emergency use.

{Matzav.com Israel}